Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals Q4 2024 Earnings Report

Eledon Pharmaceuticals logo
$3.05 +0.03 (+0.99%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.05 0.00 (0.00%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.32
One Year Ago EPS
-$1.00

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
4:00PM ET

Eledon Pharmaceuticals Earnings Headlines

What is Noble Financial's Estimate for ELDN Q2 Earnings?
Equities Analysts Issue Forecasts for ELDN FY2025 Earnings
52 Money Mondays for $7 (This Weekend Only)
Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’s “Most Wanted” trader, who just put the finishing touches on his brand-new Money Monday algorithm.
Leerink Partnrs Has Optimistic Outlook of ELDN Q2 Earnings
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat